CLLS vs. VCXB, XFOR, CRDF, CGEN, GNFT, VXRT, ADVM, CRDL, ELEV, and VIGL
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include 10X Capital Venture Acquisition Corp. III (VCXB), X4 Pharmaceuticals (XFOR), Cardiff Oncology (CRDF), Compugen (CGEN), Genfit (GNFT), Vaxart (VXRT), Adverum Biotechnologies (ADVM), Cardiol Therapeutics (CRDL), Elevation Oncology (ELEV), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.
Cellectis (NASDAQ:CLLS) and 10X Capital Venture Acquisition Corp. III (NYSE:VCXB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.
63.9% of Cellectis shares are owned by institutional investors. Comparatively, 13.3% of 10X Capital Venture Acquisition Corp. III shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 71.5% of 10X Capital Venture Acquisition Corp. III shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cellectis currently has a consensus target price of $8.50, suggesting a potential upside of 184.28%. Given Cellectis' higher possible upside, research analysts clearly believe Cellectis is more favorable than 10X Capital Venture Acquisition Corp. III.
10X Capital Venture Acquisition Corp. III has a net margin of 0.00% compared to Cellectis' net margin of -1,087.66%. 10X Capital Venture Acquisition Corp. III's return on equity of 0.00% beat Cellectis' return on equity.
In the previous week, 10X Capital Venture Acquisition Corp. III had 1 more articles in the media than Cellectis. MarketBeat recorded 1 mentions for 10X Capital Venture Acquisition Corp. III and 0 mentions for Cellectis. 10X Capital Venture Acquisition Corp. III's average media sentiment score of 1.68 beat Cellectis' score of 0.30 indicating that 10X Capital Venture Acquisition Corp. III is being referred to more favorably in the news media.
10X Capital Venture Acquisition Corp. III has lower revenue, but higher earnings than Cellectis.
Cellectis received 404 more outperform votes than 10X Capital Venture Acquisition Corp. III when rated by MarketBeat users.
Cellectis has a beta of 3.08, suggesting that its share price is 208% more volatile than the S&P 500. Comparatively, 10X Capital Venture Acquisition Corp. III has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500.
Summary
10X Capital Venture Acquisition Corp. III beats Cellectis on 7 of the 13 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
